211 related articles for article (PubMed ID: 28903178)
21. Synergistic Anti-Breast-Cancer Effects of Combined Treatment With Oleuropein and Doxorubicin In Vivo.
Elamin MH; Elmahi AB; Daghestani MH; Al-Olayan EM; Al-Ajmi RA; Alkhuriji AF; Hamed SS; Elkhadragy MF
Altern Ther Health Med; 2019 May; 25(3):17-24. PubMed ID: 28646810
[TBL] [Abstract][Full Text] [Related]
22. Chemosensitizing Properties of β-Caryophyllene and β-Caryophyllene Oxide in Combination with Doxorubicin in Human Cancer Cells.
DI Giacomo S; DI Sotto A; Mazzanti G; Wink M
Anticancer Res; 2017 Mar; 37(3):1191-1196. PubMed ID: 28314281
[TBL] [Abstract][Full Text] [Related]
23. Reversal of doxorubicin resistance in breast cancer by mitochondria-targeted pH-responsive micelles.
Yu P; Yu H; Guo C; Cui Z; Chen X; Yin Q; Zhang P; Yang X; Cui H; Li Y
Acta Biomater; 2015 Mar; 14():115-24. PubMed ID: 25498306
[TBL] [Abstract][Full Text] [Related]
24. Intratumoral expression of mature human neutrophil peptide-1 potentiates the therapeutic effect of doxorubicin in a mouse 4T1 breast cancer model.
Li D; Qin Q; Wang XY; Shi HS; Luo M; Guo FC; Wang W; Wang YS
Oncol Rep; 2014 Mar; 31(3):1287-95. PubMed ID: 24378474
[TBL] [Abstract][Full Text] [Related]
25. Improved antitumor activity and reduced toxicity of doxorubicin encapsulated in poly(ε-caprolactone) nanoparticles in lung and breast cancer treatment: An in vitro and in vivo study.
Cabeza L; Ortiz R; Prados J; Delgado ÁV; Martín-Villena MJ; Clares B; Perazzoli G; Entrena JM; Melguizo C; Arias JL
Eur J Pharm Sci; 2017 May; 102():24-34. PubMed ID: 28219748
[TBL] [Abstract][Full Text] [Related]
26. Second-generation proteasome inhibitor carfilzomib enhances doxorubicin-induced cytotoxicity and apoptosis in breast cancer cells.
Shi Y; Yu Y; Wang Z; Wang H; Bieerkehazhi S; Zhao Y; Suzuk L; Zhang H
Oncotarget; 2016 Nov; 7(45):73697-73710. PubMed ID: 27655642
[TBL] [Abstract][Full Text] [Related]
27. Tumor inhibitory effect of gefitinib (ZD1839, Iressa) and taxane combination therapy in EGFR-overexpressing breast cancer cell lines (MCF7/ADR, MDA-MB-231).
Takabatake D; Fujita T; Shien T; Kawasaki K; Taira N; Yoshitomi S; Takahashi H; Ishibe Y; Ogasawara Y; Doihara H
Int J Cancer; 2007 Jan; 120(1):181-8. PubMed ID: 17036319
[TBL] [Abstract][Full Text] [Related]
28. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP
Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702
[TBL] [Abstract][Full Text] [Related]
29. Co-delivery of IL17RB siRNA and doxorubicin by chitosan-based nanoparticles for enhanced anticancer efficacy in breast cancer cells.
Alinejad V; Hossein Somi M; Baradaran B; Akbarzadeh P; Atyabi F; Kazerooni H; Samadi Kafil H; Aghebati Maleki L; Siah Mansouri H; Yousefi M
Biomed Pharmacother; 2016 Oct; 83():229-240. PubMed ID: 27372407
[TBL] [Abstract][Full Text] [Related]
30. Peptide-Drug Conjugate Targeting Keratin 1 Inhibits Triple-Negative Breast Cancer in Mice.
Ziaei E; Paiva IM; Yao SJ; Sarrami N; Mehinrad P; Lai J; Lavasanifar A; Kaur K
Mol Pharm; 2023 Jul; 20(7):3570-3577. PubMed ID: 37307328
[TBL] [Abstract][Full Text] [Related]
31. In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells.
Ogawara K; Un K; Tanaka K; Higaki K; Kimura T
J Control Release; 2009 Jan; 133(1):4-10. PubMed ID: 18840484
[TBL] [Abstract][Full Text] [Related]
32. The tumor accumulation and therapeutic efficacy of doxorubicin carried in calcium phosphate-reinforced polymer nanoparticles.
Min KH; Lee HJ; Kim K; Kwon IC; Jeong SY; Lee SC
Biomaterials; 2012 Aug; 33(23):5788-97. PubMed ID: 22591612
[TBL] [Abstract][Full Text] [Related]
33. Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells.
Tyagi AK; Agarwal C; Chan DC; Agarwal R
Oncol Rep; 2004 Feb; 11(2):493-9. PubMed ID: 14719089
[TBL] [Abstract][Full Text] [Related]
34. Synthesis of polydopamine as a new and biocompatible coating of magnetic nanoparticles for delivery of doxorubicin in mouse breast adenocarcinoma.
Zavareh S; Mahdi M; Erfanian S; Hashemi-Moghaddam H
Cancer Chemother Pharmacol; 2016 Nov; 78(5):1073-1084. PubMed ID: 27752764
[TBL] [Abstract][Full Text] [Related]
35. Mixed micelles for encapsulation of doxorubicin with enhanced in vitro cytotoxicity on breast and ovarian cancer cell lines versus Doxil
Cagel M; Bernabeu E; Gonzalez L; Lagomarsino E; Zubillaga M; Moretton MA; Chiappetta DA
Biomed Pharmacother; 2017 Nov; 95():894-903. PubMed ID: 28903185
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis, cytocidal activity and estrogen receptor α affinity of doxorubicin conjugates at 16α-position of estrogen for site-specific treatment of estrogen receptor positive breast cancer.
Saha P; Fortin S; Leblanc V; Parent S; Asselin É; Bérubé G
Steroids; 2012 Sep; 77(11):1113-22. PubMed ID: 22801351
[TBL] [Abstract][Full Text] [Related]
37. Efficient induction of apoptosis by doxorubicin coupled to cell-penetrating peptides compared to unconjugated doxorubicin in the human breast cancer cell line MDA-MB 231.
Aroui S; Brahim S; De Waard M; Bréard J; Kenani A
Cancer Lett; 2009 Nov; 285(1):28-38. PubMed ID: 19523755
[TBL] [Abstract][Full Text] [Related]
38. Retinal-conjugated pH-sensitive micelles induce tumor senescence for boosting breast cancer chemotherapy.
Zhang Y; Li P; Pan H; Liu L; Ji M; Sheng N; Wang C; Cai L; Ma Y
Biomaterials; 2016 Mar; 83():219-32. PubMed ID: 26774567
[TBL] [Abstract][Full Text] [Related]
39. Cancer-associated fibroblasts induce high mobility group box 1 and contribute to resistance to doxorubicin in breast cancer cells.
Amornsupak K; Insawang T; Thuwajit P; O-Charoenrat P; Eccles SA; Thuwajit C
BMC Cancer; 2014 Dec; 14():955. PubMed ID: 25512109
[TBL] [Abstract][Full Text] [Related]
40. The impact of sesquiterpenes β-caryophyllene oxide and trans-nerolidol on xenobiotic-metabolizing enzymes in mice in vivo.
Lněničková K; Svobodová H; Skálová L; Ambrož M; Novák F; Matoušková P
Xenobiotica; 2018 Nov; 48(11):1089-1097. PubMed ID: 29098926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
